Literature DB >> 10468303

Expression of membrane cofactor protein (MCP, CD46) in human liver diseases.

N Kinugasa1, T Higashi, K Nouso, H Nakatsukasa, Y Kobayashi, M Ishizaki, N Toshikuni, K Yoshida, S Uematsu, T Tsuji.   

Abstract

Membrane cofactor protein (MCP, CD46) is one of the complement regulatory proteins, and is widely distributed in human organs and protects cells from complement-mediated cytotoxicity. We analysed the distribution and the intensities of MCP in liver diseases and evaluated the role of MCP during hepatocarcinogenesis. Western blot analysis revealed that relative densities (density of the sample/density of the standard sample) of MCP in 27 HCC, 18 liver cirrhosis, nine chronic hepatitis and 12 normal liver were 0.63+/-0.23, 0.21+/-0.07, 0.25+/-0.10 and 0.11+/-0.03 (mean+/-s.d.) respectively. MCP expression in hepatocellular carcinoma (HCC) was significantly higher than that in both liver cirrhosis and chronic hepatitis (P < 0.01). The difference in the tumour sizes, the grades of differentiation and viral marker status did not affect the expression. Immunohistological analysis revealed that MCP was distributed mainly in the basolateral membrane of the hepatic cord in non-cancerous liver, along with endothelial cells and bile duct cells. In HCC, the protein was observed on the membrane in a non-polarized fashion. These data suggest that HCC cells acquire the increased MCP expression in a development of HCC and may escape from tumour-specific complement-mediated cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10468303      PMCID: PMC2374269          DOI: 10.1038/sj.bjc.6690604

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  27 in total

Review 1.  The regulators of complement activation (RCA) gene cluster.

Authors:  D Hourcade; V M Holers; J P Atkinson
Journal:  Adv Immunol       Date:  1989       Impact factor: 3.543

2.  Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis.

Authors:  A Gorter; V T Blok; W H Haasnoot; N G Ensink; M R Daha; G J Fleuren
Journal:  Lab Invest       Date:  1996-06       Impact factor: 5.662

3.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

Review 4.  Decay-accelerating factor: biochemistry, molecular biology, and function.

Authors:  D M Lublin; J P Atkinson
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

5.  [Serum complement profile and its clinical significance in patients with hepatocellular carcinoma and liver cirrhosis (author's transl)].

Authors:  N Matsumura; H Tagami; T Hotta; S Takemura; T Yoshikawa; M Kondo
Journal:  Nihon Shokakibyo Gakkai Zasshi       Date:  1981-09

6.  Complement-regulatory proteins in ovarian malignancies.

Authors:  L Bjørge; J Hakulinen; T Wahlström; R Matre; S Meri
Journal:  Int J Cancer       Date:  1997-01-06       Impact factor: 7.396

7.  Expression of the complement regulatory proteins decay accelerating factor (DAF, CD55), membrane cofactor protein (MCP, CD46) and CD59 in the normal human uterine cervix and in premalignant and malignant cervical disease.

Authors:  K L Simpson; A Jones; S Norman; C H Holmes
Journal:  Am J Pathol       Date:  1997-11       Impact factor: 4.307

8.  The third (C3) and fourth (C4) components of complement in human liver. Immunocytochemical evidence for hepatocytes as the site of synthesis.

Authors:  H Nagura; H Hasegawa; S Yoshimura; K Watanabe
Journal:  Acta Pathol Jpn       Date:  1985-01

9.  Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin).

Authors:  G A Niehans; D L Cherwitz; N A Staley; D J Knapp; A P Dalmasso
Journal:  Am J Pathol       Date:  1996-07       Impact factor: 4.307

10.  Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro.

Authors:  N K Cheung; E I Walter; W H Smith-Mensah; W D Ratnoff; M L Tykocinski; M E Medof
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

View more
  27 in total

1.  Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors.

Authors:  Dmitry M Shayakhmetov; Zong-Yi Li; Shaoheng Ni; André Lieber
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

2.  Deletion of penton RGD motifs affects the efficiency of both the internalization and the endosome escape of viral particles containing adenovirus serotype 5 or 35 fiber knobs.

Authors:  Dmitry M Shayakhmetov; Andrea M Eberly; Zong-Yi Li; André Lieber
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

3.  Localization of regions in CD46 that interact with adenovirus.

Authors:  Anuj Gaggar; Dmitry M Shayakhmetov; M Kathryn Liszewski; John P Atkinson; André Lieber
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

4.  Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons.

Authors:  Shaoheng Ni; Kathrin Bernt; Anuj Gaggar; Zong-Yi Li; Hans-Peter Kiem; André Lieber
Journal:  Hum Gene Ther       Date:  2005-06       Impact factor: 5.695

5.  Hepatitis C virus infection upregulates CD55 expression on the hepatocyte surface and promotes association with virus particles.

Authors:  Budhaditya Mazumdar; Hangeun Kim; Keith Meyer; Sandip K Bose; Adrian M Di Bisceglie; Ratna B Ray; Michael S Diamond; John P Atkinson; Ranjit Ray
Journal:  J Virol       Date:  2013-05-08       Impact factor: 5.103

6.  Chimeric adenoviral vectors incorporating a fiber of human adenovirus 3 efficiently mediate gene transfer into prostate cancer cells.

Authors:  Miho Murakami; Hideyo Ugai; Natalya Belousova; Alexander Pereboev; Paul Dent; Paul B Fisher; Maaike Everts; David T Curiel
Journal:  Prostate       Date:  2010-03-01       Impact factor: 4.104

7.  A recombinant adenovirus type 35 fiber knob protein sensitizes lymphoma cells to rituximab therapy.

Authors:  Hongjie Wang; Ying Liu; Zong-Yi Li; Xiaolong Fan; Akseli Hemminki; André Lieber
Journal:  Blood       Date:  2009-11-12       Impact factor: 22.113

8.  Influence of coagulation factor x on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5/Ad35 vectors.

Authors:  Jenny A Greig; Suzanne Mk Buckley; Simon N Waddington; Alan L Parker; David Bhella; Rebecca Pink; Ahad A Rahim; Takashi Morita; Stuart A Nicklin; John H McVey; Andrew H Baker
Journal:  Mol Ther       Date:  2009-07-14       Impact factor: 11.454

Review 9.  The dual role of complement in cancer and its implication in anti-tumor therapy.

Authors:  Ioannis Kourtzelis; Stavros Rafail
Journal:  Ann Transl Med       Date:  2016-07

10.  Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles.

Authors:  Han Hsi Wong; Nicholas R Lemoine; Yaohe Wang
Journal:  Viruses       Date:  2010-01       Impact factor: 5.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.